Tema Etfs LLC Makes New $1.20 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Tema Etfs LLC bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 44,343 shares of the company's stock, valued at approximately $1,203,000. Tema Etfs LLC owned approximately 0.08% of Structure Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company's stock worth $3,562,000 after acquiring an additional 31,815 shares during the period. JPMorgan Chase & Co. increased its holdings in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company's stock valued at $1,489,000 after purchasing an additional 25,500 shares in the last quarter. Janney Capital Management LLC increased its position in Structure Therapeutics by 36.4% in the 4th quarter. Janney Capital Management LLC now owns 9,007 shares of the company's stock valued at $244,000 after acquiring an additional 2,405 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Structure Therapeutics by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,634 shares of the company's stock worth $343,000 after acquiring an additional 1,174 shares during the last quarter. Finally, Spire Wealth Management acquired a new position in shares of Structure Therapeutics during the fourth quarter worth approximately $243,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Analysts Set New Price Targets

Several research analysts have issued reports on GPCR shares. William Blair initiated coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright cut their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $78.00.

Structure Therapeutics Trading Down 2.1%

Shares of GPCR stock traded down $0.52 during trading hours on Wednesday, hitting $24.15. 581,820 shares of the company were exchanged, compared to its average volume of 933,738. The company has a market capitalization of $1.38 billion, a PE ratio of -32.63 and a beta of -1.69. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $62.74. The business has a 50 day moving average of $21.34 and a two-hundred day moving average of $26.24.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.